117.12
price up icon3.34%   3.79
after-market アフターアワーズ: 116.00 -1.12 -0.96%
loading
前日終値:
$113.33
開ける:
$113.1
24時間の取引高:
1.33M
Relative Volume:
1.63
時価総額:
$7.10B
収益:
$3.99B
当期純損益:
$463.16M
株価収益率:
16.50
EPS:
7.1
ネットキャッシュフロー:
$1.10B
1週間 パフォーマンス:
+10.56%
1か月 パフォーマンス:
+6.21%
6か月 パフォーマンス:
-14.40%
1年 パフォーマンス:
+4.87%
1日の値動き範囲:
Value
$112.49
$117.21
1週間の範囲:
Value
$106.65
$117.21
52週間の値動き範囲:
Value
$95.49
$148.06

Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile

Name
名前
Jazz Pharmaceuticals Plc
Name
セクター
Healthcare (1161)
Name
電話
353-1-634-7800
Name
住所
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Name
職員
2,800
Name
Twitter
@jazzpharma
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
JAZZ's Discussions on Twitter

JAZZ を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
JAZZ
Jazz Pharmaceuticals Plc
117.12 6.87B 3.99B 463.16M 1.10B 7.10
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.92 99.42B 11.42B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.55 58.99B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
432.52 56.35B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
646.60 39.02B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
307.51 34.25B 3.81B -644.79M -669.77M -6.24

Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-07-15 開始されました Deutsche Bank Buy
2025-03-07 アップグレード UBS Neutral → Buy
2025-02-26 ダウングレード Cantor Fitzgerald Overweight → Neutral
2025-02-13 アップグレード Wells Fargo Equal Weight → Overweight
2024-12-12 アップグレード Morgan Stanley Equal-Weight → Overweight
2024-06-05 開始されました Goldman Buy
2024-01-03 開始されました Robert W. Baird Outperform
2023-11-27 ダウングレード UBS Buy → Neutral
2023-09-29 開始されました Raymond James Mkt Perform
2023-06-12 再開されました Wells Fargo Equal Weight
2022-12-09 アップグレード Goldman Neutral → Buy
2022-06-14 開始されました UBS Buy
2022-04-06 ダウングレード Goldman Buy → Neutral
2021-11-19 再開されました Goldman Buy
2021-10-07 再開されました Jefferies Buy
2021-10-05 開始されました Citigroup Buy
2021-09-23 開始されました Needham Buy
2021-05-19 再開されました JP Morgan Overweight
2021-04-07 再開されました RBC Capital Mkts Outperform
2021-02-05 繰り返されました H.C. Wainwright Buy
2021-02-03 アップグレード Piper Sandler Neutral → Overweight
2021-01-29 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-12-16 開始されました UBS Buy
2020-11-03 繰り返されました H.C. Wainwright Buy
2020-10-09 繰り返されました H.C. Wainwright Buy
2020-09-14 ダウングレード Goldman Neutral → Sell
2020-09-14 再開されました JP Morgan Overweight
2020-08-06 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-07-28 アップグレード Wolfe Research Peer Perform → Outperform
2020-07-23 アップグレード H.C. Wainwright Neutral → Buy
2020-04-06 開始されました Jefferies Buy
2020-03-12 アップグレード Bernstein Mkt Perform → Outperform
2020-01-08 開始されました Goldman Neutral
2019-08-21 ダウングレード Piper Jaffray Overweight → Neutral
2019-06-11 開始されました Barclays Overweight
2019-03-20 開始されました SunTrust Buy
2018-12-14 開始されました Wolfe Research Peer Perform
2018-11-08 繰り返されました B. Riley FBR Buy
2018-08-08 繰り返されました Stifel Buy
2018-07-11 ダウングレード Morgan Stanley Overweight → Equal-Weight
2018-03-23 繰り返されました H.C. Wainwright Neutral
2018-03-19 アップグレード Morgan Stanley Equal-Weight → Overweight
すべてを表示

Jazz Pharmaceuticals Plc (JAZZ) 最新ニュース

pulisher
05:02 AM

Is FDA’s First-Ever Approval of Modeyso Shaping the Investment Case for Jazz Pharmaceuticals (JAZZ)? - simplywall.st

05:02 AM
pulisher
Aug 11, 2025

Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight - GlobeNewswire Inc.

Aug 11, 2025
pulisher
Aug 11, 2025

Jazz Pharma wins FDA nod for Modeyso against rare brain tumor - MSN

Aug 11, 2025
pulisher
Aug 10, 2025

Jazz Pharmaceuticals projects late Q4 zanidatamab Phase III data, signals leadership transition and updates 2025 guidance - MSN

Aug 10, 2025
pulisher
Aug 10, 2025

Using flow based indicators on Jazz Pharmaceuticals plcTechnical Analysis of Growth Stock Opportunities - Newser

Aug 10, 2025
pulisher
Aug 09, 2025

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st

Aug 09, 2025
pulisher
Aug 08, 2025

Jazz Pharmaceuticals gets EU nod for Ziihera - MSN

Aug 08, 2025
pulisher
Aug 08, 2025

Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com

Aug 08, 2025
pulisher
Aug 08, 2025

Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock - Yahoo Finance

Aug 08, 2025
pulisher
Aug 08, 2025

FDA Grants Accelerated Approval to Dordaviprone For Diffuse Midline Glioma - Pharmacy Times

Aug 08, 2025
pulisher
Aug 08, 2025

How to integrate Jazz Pharmaceuticals plc into portfolio analysis tools - Newser

Aug 08, 2025
pulisher
Aug 07, 2025

Jazz’s Modeyso Approved For Rare Glioma With Expansion Targeted - insights.citeline.com

Aug 07, 2025
pulisher
Aug 07, 2025

Jazz Pharmaceuticals stock surges 4.8% on FDA approval for Modeyso treatment - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Jazz Pharma wins FDA nod for brain tumor drug (JAZZ:NASDAQ) - Seeking Alpha

Aug 07, 2025
pulisher
Aug 07, 2025

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 07, 2025
pulisher
Aug 07, 2025

FDA approval of Modeyso for glioma - The Pharma Letter

Aug 07, 2025
pulisher
Aug 07, 2025

Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results - TradingView

Aug 07, 2025
pulisher
Aug 07, 2025

JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut - MSN

Aug 07, 2025
pulisher
Aug 07, 2025

FDA gives accelerated approval to Jazz Pharma’s diffuse midline glioma therapy - Pharmaceutical Technology

Aug 07, 2025
pulisher
Aug 07, 2025

Beyond the Balance Sheet: What SWOT Reveals About Jazz Pharmaceu - GuruFocus

Aug 07, 2025
pulisher
Aug 06, 2025

Jazz Earnings: Xywav and Epidiolex Drive Growth; US Approval for Chimerix's Dordaviprone Promising - Morningstar

Aug 06, 2025
pulisher
Aug 06, 2025

Chimerix buyout a win for Jazz with FDA nod for rare glioma drug - BioWorld MedTech

Aug 06, 2025
pulisher
Aug 06, 2025

US FDA approves Jazz Pharma's drug for rare brain tumor - Reuters

Aug 06, 2025
pulisher
Aug 06, 2025

Rising Star: Quinn Emanuel's Frank Calvosa - Law360

Aug 06, 2025
pulisher
Aug 06, 2025

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma - PR Newswire

Aug 06, 2025
pulisher
Aug 06, 2025

Jazz Pharmaceuticals plc SEC 10-Q Report - TradingView

Aug 06, 2025
pulisher
Aug 06, 2025

What data driven models say about Jazz Pharmaceuticals plc’s futureFree Triple Digit Return Stock Predictions - Newser

Aug 06, 2025
pulisher
Aug 06, 2025

Jazz Pharmaceuticals plc 2025 Q2ResultsEarnings Call Presentation (NASDAQ:JAZZ) - Seeking Alpha

Aug 06, 2025
pulisher
Aug 06, 2025

Jazz Pharmaceuticals PLC (JAZZ) Q2 2025 Earnings Call Highlights: Strong Neuroscience ... By GuruFocus - Investing.com Canada

Aug 06, 2025
pulisher
Aug 06, 2025

Jazz: Q2 Earnings Snapshot - Greenwich Time

Aug 06, 2025
pulisher
Aug 06, 2025

Jazz Pharmaceuticals PLC (JAZZ) Q2 2025 Earnings Call Highlights: Strong Neuroscience ... - Yahoo Finance

Aug 06, 2025
pulisher
Aug 06, 2025

Jazz Pharmaceuticals plc Earnings Report Breakdown: What Investors Should KnowTechnical Analysis of Growth Stock Opportunities - Newser

Aug 06, 2025
pulisher
Aug 06, 2025

Using data tools to time your Jazz Pharmaceuticals plc exitFree Wealth Building Stock Market Ideas - Newser

Aug 06, 2025
pulisher
Aug 06, 2025

Jazz Pharmaceuticals Reports Q2 2025 Results and CEO Transition - TipRanks

Aug 06, 2025
pulisher
Aug 06, 2025

Jazz Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat

Aug 06, 2025
pulisher
Aug 05, 2025

Jazz Pharmaceuticals Sticks To Its Game Plan Despite Setbacks - Finimize

Aug 05, 2025
pulisher
Aug 05, 2025

Jazz (JAZZ) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance

Aug 05, 2025
pulisher
Aug 05, 2025

Jazz Pharmaceuticals PLC reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 05, 2025
pulisher
Aug 05, 2025

Transcript : Jazz Pharmaceuticals plc, Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener

Aug 05, 2025
pulisher
Aug 05, 2025

Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

Aug 05, 2025
pulisher
Aug 05, 2025

Jazz Pharmaceuticals misses on Q2 earnings, shares fall By Investing.com - Investing.com South Africa

Aug 05, 2025
pulisher
Aug 05, 2025

Jazz Pharmaceuticals misses on Q2 earnings, shares fall - Investing.com

Aug 05, 2025
pulisher
Aug 05, 2025

Jazz Pharma earnings missed by $0.63, revenue topped estimates - Investing.com South Africa

Aug 05, 2025
pulisher
Aug 05, 2025

Jazz Pharmaceuticals Q2 revenue up 2% - MarketScreener

Aug 05, 2025
pulisher
Aug 05, 2025

Earnings Flash (JAZZ) Jazz Pharmaceuticals plc Posts Q2 Adjusted Loss $8.25 per Share, vs. FactSet Est Loss of $7.61 - MarketScreener

Aug 05, 2025
pulisher
Aug 05, 2025

Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance - PR Newswire

Aug 05, 2025
pulisher
Aug 05, 2025

Narcolepsy Market to Reach New Heights in Growth by 2034, - openPR.com

Aug 05, 2025
pulisher
Aug 05, 2025

Narcolepsy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts| Taisho Pharmaceutical, Jazz Pharma, Suven Life Sciences Limited, Alza Corporation, Cephalon, Orphan Medical - Barchart.com

Aug 05, 2025
pulisher
Aug 05, 2025

Jazz Pharmaceuticals (NASDAQ:JAZZ) investors are sitting on a loss of 25% if they invested three years ago - Yahoo Finance

Aug 05, 2025
pulisher
Aug 05, 2025

How Jazz Pharmaceuticals plc stock reacts to Fed policy changesSwing Entry Insight With Forecast Accuracy - Newser

Aug 05, 2025
pulisher
Aug 04, 2025

What MACD signals say about Jazz Pharmaceuticals plcOversold Opportunity Scanner with RSI Data - Newser

Aug 04, 2025

Jazz Pharmaceuticals Plc (JAZZ) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$36.46
price up icon 1.67%
$85.85
price up icon 5.20%
$26.87
price up icon 4.61%
$122.87
price up icon 0.71%
$112.78
price up icon 1.60%
biotechnology ONC
$307.51
price up icon 6.74%
大文字化:     |  ボリューム (24 時間):